Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, shares his extensive experience in RNA medicine and drug development. He discusses the critical transition from academia to industry and the rigorous pharmaceutical standards that govern clinical trials. Ticho emphasizes the importance of patient-centered approaches to therapy and reveals insights on evaluating drug programs. His thoughts on the adaptability required in biotech highlight the challenges and opportunities in the rapidly evolving landscape of modern medicine.